文献速递核素与放射性配体治疗

225Ac-DOTATATE靶向α治疗转移性副神经节瘤的疗效与安全性:一项先导研究

Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-27

这项先导研究纳入9例经组织学证实的晚期副神经节瘤(PGL)患者,每8周接受一次225Ac-DOTATATE靶向α治疗(TAT)并联合卡培他滨放疗增敏,累计活度约74 MBq。结果显示形态学部分缓解50%、疾病稳定37.5%、疾病进展12.5%,疾病控制率(DCR)87.5%;既往177Lu-PRRT失败者形态学DCR为66.6%(2/3)。未观察到III/IV级血液学、肾脏及肝脏毒性。

要点

  • 9例晚期PGL接受225Ac-DOTATATE联合卡培他滨治疗,形态学DCR达87.5%。
  • 既往177Lu-PRRT失败患者中形态学DCR为66.6%(2/3)。
  • 未观察到III/IV级血液学、肾脏及肝脏毒性。

核心结论

  • 本研究证据提示225Ac-DOTATATE治疗晚期PGL有效且安全,对既往177Lu-PRRT难治患者也报告了明确获益。

研究设计与样本

  • 先导研究,连续纳入9例(6男3女)经组织学证实的PGL患者,接受225Ac-DOTATATE靶向α治疗并联合卡培他滨放疗增敏,每8周一次,累计活度约74 MBq。

主要发现

  • 形态学疗效:部分缓解50%、疾病稳定37.5%、疾病进展12.5%,DCR为87.5%。
  • 既往177Lu-PRRT失败患者的形态学DCR为66.6%(2/3)。
  • 抗高血压药物停用25%、减量37.5%;KPS、ECOG及镇痛评分(AS)治疗后明显改善。
  • 7例头颈部PGL患者的QLQ-H&N35症状评分在所有方面显著改善;性功能无改善(P=0.3559)。
  • 镇痛评分治疗后显著降低(P=0.0031),但QLQ-H&N35关于止痛药摄入仅边缘显著(P=0.1723)。

关键数值与推荐

  • 主要终点采用RECIST 1.1标准评估疗效反应和疾病控制率(DCR)。
  • 安全性按CTCAE 5.0版标准评估,未观察到III/IV级血液学、肾脏及肝脏毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study, we aim to evaluate the efficacy and safety of 225AC-DOTATATE targeted alpha therapy in advanced-stage paragangliomas (PGLs). METHODS: Nine (6 males and 3 females) consecutive patients with histologically proven PGLs were treated with 225Ac-DOTATATE targeted alpha therapy (TAT) and concomitant radiosensitizer, capecitabine, at 8-weekly intervals up to a cumulative activity of ~ 74 MBq. The primary endpoint included evaluating therapy response and disease control rate (DCR) using the RECIST 1.1 criteria. Additional secondary endpoints comprised clinical response assessment using EORTC QLQ-H&N35 questionnaire, Karnofsky Performance Scale (KPS), Eastern Cooperative Oncology Group performance status (ECOG), analgesic score (AS), dose alterations of anti-hypertensive drugs (anti-HTN), and the safety and side-effect profile evaluation as per CTCAE criteria version 5.0. RESULTS: Following 225Ac-DOTATATE treatment, morphological response revealed partial response in 50%, stable disease in 37.5%, and disease progression in 12.5%, with a DCR of 87.5%. Similarly, the symptomatic response was remarkable, and anti-HTN drugs were stopped in 25% and reduced in 37.5%. Another significant finding in our study revealed a morphologic DCR of 66.6% (2/3) in patients who failed previous lutetium-177 peptide receptor radionuclide therapy (177Lu-PRRT). Regarding the KPS, ECOG, and AS performance scores, a notable improvement was observed post-225Ac-DOTATATE treatment. The QLQ-H&N35 symptom scores evaluated in seven H&N PGL patients showed significant improvement in all aspects. No improvement in sexual function was noted (P = 0.3559). Despite the significant reduction in the analgesic score post-treatment (P = 0.0031), the QLQ-H&N35 revealed only marginal significance concerning the intake of pain killers (P = 0.1723). No grade III/IV hematological, renal, and hepatological toxicities were noted. CONCLUSION: The evidence from this study suggests 225Ac-DOTATATE therapy is effective and safe in the treatment of advanced-stage PGLs and also reports a clear benefit even in patient's refractory to the previous 177Lu-PRRT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34837103. doi:10.1007/s00259-021-05632-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。